Surrozen, Inc. (SRZNW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Surrozen, Inc. (SRZNW) is a biotechnology firm dedicated to discovering and developing drug candidates designed to selectively modulate the Wnt pathway for the purpose of tissue repair. The company operates within the biotechnology sector, focusing on the development of antibody-based therapeutics that target diverse disease areas including conditions affecting the intestine, liver, retina, cornea, and lung. Despite its specialized focus on tissue repair technologies, the company reports a market capitalization of N/A and has generated annual revenue of $3.48 million over the trailing twelve months. The organization employs a workforce of 44 individuals to support its research and development initiatives. The reported market capitalization of N/A suggests that the company is either pre-revenue or trading at a level where standard valuation multiples are not applicable, while the $3.48 million in revenue indicates a small-scale operation typical of early-stage biotechnology entities. With only 44 employees, the company maintains a lean operational structure to manage its cash resources and advance its pipeline of antibody-based therapeutics.

वित्तीय स्वास्थ्य

The company reported a revenue of $3.48 million for the trailing twelve months, yet it recorded a net income of $-242,026,000, creating a significant disparity that reveals a highly aggressive cost structure or substantial non-operating expenses. This massive loss relative to revenue highlights the capital-intensive nature of biotechnology development, where research costs often exceed immediate sales figures. The company's EBITDA stands at $-41,555,000, indicating that even before interest and tax considerations, the core business operations are currently generating negative cash conversion. Free cash flow is reported at $-16,856,500, which signifies that the company is consuming cash reserves to fund its operations and development programs rather than generating liquidity. The balance sheet shows a cash position of $89.25 million against total debt of $6.64 million, providing a substantial liquidity buffer despite the negative earnings. The debt-to-equity ratio is listed as N/A, likely due to the negative equity position inherent in the reported net losses. The current ratio is 9.22, which indicates an extremely strong short-term liquidity position with current assets significantly exceeding current liabilities. Return on Assets is -35.7%, while Return on Equity is N/A, reflecting the fact that the company has not yet achieved profitability to generate returns on shareholder capital or total assets.

मूल्यांकन आकलन

The trailing P/E ratio is N/A due to the negative earnings, and the forward P/E is also N/A, implying that standard earnings-based valuation multiples cannot be applied given the current financial performance. The price-to-book ratio is reported as -0.00, which indicates a negative book value per share that precludes the calculation of a traditional market premium over book value. The price-to-sales ratio is N/A, and the EV/EBITDA is also N/A, suggesting that alternative valuation metrics based on earnings or sales multiples are not applicable at this stage of the company's development. The 52-week high is $0.02 and the 52-week low is $0.02, meaning the stock is trading within a narrow range with no price movement over the past year. Since the high and low are identical at $0.02, the current trading price is effectively at the midpoint of this static range, reflecting a lack of market price discovery or volatility. The beta value is 0.52, which indicates that the stock price is less volatile than the broader market, moving at approximately half the magnitude of the market index.

Growth & Income

Revenue growth year-over-year is -19.4%, while earnings growth is N/A due to the reported losses, indicating that the company is contracting in revenue rather than expanding its sales base. The negative revenue growth suggests a decline in sales or a shift in business model, which is common in biotechnology firms transitioning between development phases but requires careful monitoring of cash reserves. The company does not pay dividends, as the dividend yield is N/A and the payout ratio is N/A, meaning it retains all available cash for reinvestment into its drug discovery pipeline. This reinvestment strategy is typical for biotechnology companies that prioritize funding research and development over returning capital to shareholders. The overall growth and income profile is characterized by negative revenue growth, significant cash consumption, and a complete absence of dividend income, reflecting the high-risk, high-reward nature of early-stage biotechnology ventures.